Chemo-immunotherapy and cognition in head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial is studying whether a combination of chemotherapy (carboplatin and paclitaxel) and an immunotherapy drug (anti-PD-1) affects memory and thinking in people with head and neck cancer that can be removed with surgery. Researchers want to see if these treatments cause any cognitive changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with head and neck squamous cell carcinoma, stages I to IVA, and have not started any treatment yet.
- You will have surgery alone or surgery plus chemotherapy and immunotherapy.
- You can speak and read Chinese.
- You do not have any brain tumors, brain injuries, or history of stroke.
- You do not have active mental illness, alcohol abuse, or dementia-related conditions (like Alzheimer's or Parkinson's).
- You are not currently taking or have not recently taken antidepressants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.